Sitamaquine (tosylate)

Sitamaquine (WR6026) tosylate, an orally active 8-aminoquinoline analog, is an antileishmanial agent. Sitamaquine tosylate inhibits mitochondrial complex II (succinate dehydrogenase) . Sitamaquine tosylate is a lipophilic weak base that rapidly accumulates in acidic compartments of Leishmania spp., mainly in acidocalcisomes[1][2].

Product Specifications

CAS Number

[1019640-33-5]

Product Name Alternative

WR 6026 (tosylate)

UNSPSC

12352005

Hazard Statement

H301-H317-H318

Target

Mitochondrial Metabolism; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/sitamaquine-tosylate.html

Solubility

10 mM in DMSO

Smiles

CC1=CC=NC2=C(NCCCCCCN(CC)CC)C=C(OC)C=C12.O=S(C3=CC=C(C)C=C3)(O)=O

Molecular Formula

C28H41N3O4S

Molecular Weight

515.71

Precautions

P261-P264-P270-P272-P280-P302+P352-P305+P351+P338-P330-P362+P364-P405-P501

References & Citations

[1]López-Martín C, et al. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob Agents Chemother. 2008;52 (11) :4030-4036.|[2]Luis Carvalho, et al. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob Agents Chemother. 2011 Sep;55 (9) :4204-10.